These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1981 related articles for article (PubMed ID: 35039461)
1. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461 [TBL] [Abstract][Full Text] [Related]
2. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008 [TBL] [Abstract][Full Text] [Related]
3. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
4. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020 [TBL] [Abstract][Full Text] [Related]
5. Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy. Tang R; He H; Lin X; Wu N; Wan L; Chen Q; Hu Y; Cheng C; Cao Y; Guo X; Zhou Y; Xiong X; Zheng M; Wang Q; Li F; Zhou Y; Li P J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650023 [TBL] [Abstract][Full Text] [Related]
6. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Nan Y; Bai Y; Hu X; Zhou K; Wu T; Zhu A; Li M; Dou Z; Cao Z; Zhang X; Xu S; Zhang Y; Lin J; Zeng X; Fan J; Zhang X; Wang X; Ju D J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39231544 [TBL] [Abstract][Full Text] [Related]
7. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977 [TBL] [Abstract][Full Text] [Related]
8. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108 [TBL] [Abstract][Full Text] [Related]
9. Exercise Training Improves Tumor Control by Increasing CD8 Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688 [TBL] [Abstract][Full Text] [Related]
10. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. O'Connell BC; Hubbard C; Zizlsperger N; Fitzgerald D; Kutok JL; Varner J; Ilaria R; Cobleigh MA; Juric D; Tkaczuk KHR; Elias A; Lee A; Dakhil S; Hamilton E; Soliman H; Peluso S J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39214650 [TBL] [Abstract][Full Text] [Related]
11. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors. Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491 [No Abstract] [Full Text] [Related]
12. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748 [TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
14. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097 [TBL] [Abstract][Full Text] [Related]
15. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Hack SP; Zhu AX; Wang Y Front Immunol; 2020; 11():598877. PubMed ID: 33250900 [TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of anti-miRNA21 sensitizes PD-L1 Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018 [No Abstract] [Full Text] [Related]
17. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related]
18. Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment. Xiang Y; Tang L; Pang H; Xu H; He Y; Feng Y; Ju L; Zhang L; Wang D Int J Nanomedicine; 2024; 19():6677-6692. PubMed ID: 38975322 [TBL] [Abstract][Full Text] [Related]
19. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy. Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]